BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 22965591)

  • 1. Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab.
    Bressler SB; Qin H; Beck RW; Chalam KV; Kim JE; Melia M; Wells JA;
    Arch Ophthalmol; 2012 Sep; 130(9):1153-61. PubMed ID: 22965591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Five-Year Outcomes of Ranibizumab With Prompt or Deferred Laser Versus Laser or Triamcinolone Plus Deferred Ranibizumab for Diabetic Macular Edema.
    Bressler SB; Glassman AR; Almukhtar T; Bressler NM; Ferris FL; Googe JM; Gupta SK; Jampol LM; Melia M; Wells JA;
    Am J Ophthalmol; 2016 Apr; 164():57-68. PubMed ID: 26802783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results.
    ; Elman MJ; Qin H; Aiello LP; Beck RW; Bressler NM; Ferris FL; Glassman AR; Maturi RK; Melia M
    Ophthalmology; 2012 Nov; 119(11):2312-8. PubMed ID: 22999634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.
    Elman MJ; Bressler NM; Qin H; Beck RW; Ferris FL; Friedman SM; Glassman AR; Scott IU; Stockdale CR; Sun JK;
    Ophthalmology; 2011 Apr; 118(4):609-14. PubMed ID: 21459214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.
    ; Elman MJ; Aiello LP; Beck RW; Bressler NM; Bressler SB; Edwards AR; Ferris FL; Friedman SM; Glassman AR; Miller KM; Scott IU; Stockdale CR; Sun JK
    Ophthalmology; 2010 Jun; 117(6):1064-1077.e35. PubMed ID: 20427088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial.
    Bressler SB; Qin H; Melia M; Bressler NM; Beck RW; Chan CK; Grover S; Miller DG;
    JAMA Ophthalmol; 2013 Aug; 131(8):1033-40. PubMed ID: 23807371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment.
    Bressler SB; Ayala AR; Bressler NM; Melia M; Qin H; Ferris FL; Flaxel CJ; Friedman SM; Glassman AR; Jampol LM; Rauser ME;
    JAMA Ophthalmol; 2016 Mar; 134(3):278-85. PubMed ID: 26746868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema.
    Nepomuceno AB; Takaki E; Paes de Almeida FP; Peroni R; Cardillo JA; Siqueira RC; Scott IU; Messias A; Jorge R
    Am J Ophthalmol; 2013 Sep; 156(3):502-510.e2. PubMed ID: 23795985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized trial to assess functional and structural effects of ranibizumab versus laser in diabetic macular edema (the LUCIDATE study).
    Comyn O; Sivaprasad S; Peto T; Neveu MM; Holder GE; Xing W; Bunce CV; Patel PJ; Egan CA; Bainbridge JW; Hykin PG
    Am J Ophthalmol; 2014 May; 157(5):960-70. PubMed ID: 24531025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Factors Associated with Vision and Edema Outcomes.
    Bressler SB; Beaulieu WT; Glassman AR; Gross JG; Melia M; Chen E; Pavlica MR; Jampol LM;
    Ophthalmology; 2018 Nov; 125(11):1776-1783. PubMed ID: 29980333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results.
    Elman MJ; Ayala A; Bressler NM; Browning D; Flaxel CJ; Glassman AR; Jampol LM; Stone TW;
    Ophthalmology; 2015 Feb; 122(2):375-81. PubMed ID: 25439614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema.
    Wells JA; Glassman AR; Jampol LM; Aiello LP; Antoszyk AN; Baker CW; Bressler NM; Browning DJ; Connor CG; Elman MJ; Ferris FL; Friedman SM; Melia M; Pieramici DJ; Sun JK; Beck RW;
    JAMA Ophthalmol; 2016 Feb; 134(2):127-34. PubMed ID: 26605836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RETINAL LAYER RESPONSE TO RANIBIZUMAB DURING TREATMENT OF DIABETIC MACULAR EDEMA: Thinner is Not Always Better.
    Ebneter A; Wolf S; Abhishek J; Zinkernagel MS
    Retina; 2016 Jul; 36(7):1314-23. PubMed ID: 26735563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal injection of ranibizumab during cataract surgery in patients with diabetic macular edema.
    Rauen PI; Ribeiro JA; Almeida FP; Scott IU; Messias A; Jorge R
    Retina; 2012 Oct; 32(9):1799-803. PubMed ID: 22495327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation.
    ; Googe J; Brucker AJ; Bressler NM; Qin H; Aiello LP; Antoszyk A; Beck RW; Bressler SB; Ferris FL; Glassman AR; Marcus D; Stockdale CR
    Retina; 2011 Jun; 31(6):1009-27. PubMed ID: 21394052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of Functional and Anatomic Outcomes in Patients with Diabetic Macular Edema Treated with Ranibizumab.
    Sophie R; Lu N; Campochiaro PA
    Ophthalmology; 2015 Jul; 122(7):1395-401. PubMed ID: 25870079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical Trial.
    Glassman AR; Baker CW; Beaulieu WT; Bressler NM; Punjabi OS; Stockdale CR; Wykoff CC; Jampol LM; Sun JK;
    JAMA Ophthalmol; 2020 Apr; 138(4):341-349. PubMed ID: 32077907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study.
    Schmidt-Erfurth U; Lang GE; Holz FG; Schlingemann RO; Lanzetta P; Massin P; Gerstner O; Bouazza AS; Shen H; Osborne A; Mitchell P;
    Ophthalmology; 2014 May; 121(5):1045-53. PubMed ID: 24491642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors influencing clinical outcomes in patients with diabetic macular edema treated with intravitreal ranibizumab: comparison between responder and non-responder cases.
    Chen YP; Wu AL; Chuang CC; Chen SN
    Sci Rep; 2019 Jul; 9(1):10952. PubMed ID: 31358777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted Retinal Photocoagulation for Diabetic Macular Edema with Peripheral Retinal Nonperfusion: Three-Year Randomized DAVE Trial.
    Brown DM; Ou WC; Wong TP; Kim RY; Croft DE; Wykoff CC;
    Ophthalmology; 2018 May; 125(5):683-690. PubMed ID: 29336896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.